Thermo Fisher’s Oncomine Dx Receives FDA Premarket Approval
The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic.
Read MorePosted by Toni Mitchell | Sep 20, 2021 | Lung Cancer |
The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic.
Read MorePosted by Toni Mitchell | Sep 14, 2021 | Lung Cancer |
A recent report showed less than half of community oncologists used biomarker testing for lung cancer — compared to 73% of academic clinicians.
Read MorePosted by Chris Wolski | Sep 3, 2021 | Disease States |
New research has uncovered a precision medicine test to identify a patient subgroup of a rare blood disorder who are more likely to respond to treatment.
Read MorePosted by Chris Wolski | Sep 2, 2021 | Prostate |
During the pandemic, studies have shown many men are missing or delaying routine health screenings, including prostate cancer screenings.
Read MorePosted by Chris Wolski | Sep 1, 2021 | Cancer |
New diagnoses of eight common types of cancer significantly declined during most of the first 13 months of the pandemic.
Read More